Product Description
Mechanisms of Action: APOC3 Inhibitor,CCR2 Antagonist,CCR5 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NeuroBo Pharmaceuticals
Company Location: BOSTON MA 02116
Company CEO: Ben Gil Price
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Liver Diseases, Alcoholic|Hypertriglyceridemia|Fatty Liver, Alcoholic|Lipodystrophy, Familial Partial|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Hypercholesterolemia|Non-alcoholic Fatty Liver Disease|Hyperlipoproteinemia Type II|Insulin Resistance|Dyslipidemia
Phase 1: Hypercholesterolemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IRB00099844 | P2 |
Terminated |
Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic |
2019-08-27 |
|
| FPLD | P2 |
Completed |
Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Lipodystrophy, Familial Partial|Hypertriglyceridemia|Non-alcoholic Steatohepatitis |
2019-07-31 |
|
| INDIGO-1 | P2 |
Completed |
Dyslipidemia|Hypertriglyceridemia |
2018-01-11 |
|
| ROYAL-1 | P2 |
Completed |
Hypercholesterolemia |
2017-06-01 |